English
Back
Open Account
BRONCUS
wrote a column · Jan 13 10:11

Registration Progress |堃博医疗 Achieves Dual Breakthroughs in the Asian Market, Multiple Products Approved in Hong Kong and Indonesia

Hong Kong
Recently, the self-developedBroncAblate® Zhiheng® Pulmonary Radiofrequency Ablation System(including radiofrequency treatment equipment and single-use pulmonary radiofrequency ablation catheters, hereinafter referred to as 'Zhiheng®') has officially been listed in the Hong Kong Department of Health’s medical device registry (registration approval). This marks the formal commercial rollout in Hong Kong of the world's first natural-orifice radiofrequency ablation interventional device for lung cancer. Concurrently,FleXNeedleCN Single-Use Endoscopic Suction Biopsy Needlealso received registration approval from the Hong Kong Department of Health’s medical device registry.
Hong Kong Recently, the self-developed product by堃博医疗,BroncAblate®智衡® Lung Radiofrequency Ablation System(including radiofrequency treatment equipment and a disposable lung radiofrequency ablation catheter, hereinafter referred to as '智衡®') has officially obtained the Hong Kong Department of Health Medical Device Listing (registration approval). This marks the formal commercial launch in Hong Kong of the world's first trans-natural airway radiofrequency ablation device for lung cancer interventional therapy. Concurrently,FleXNeedleCN Disposable Endoscopic Aspiration Biopsy Needlealso received the Hong Kong Department of Health Medical Device Listing (registration approval). Following the approval of products such as Lung Point Plus, Archimedes, and 途扩®BroncTru® in Hong Kong, more innovative products from堃博医疗 have entered Hong Kong’s precision lung interventional diagnostics and treatment market, enriching the regional product portfolio and providing new precise interventional diagnosis and treatment options for local lung disease patients. Indonesia Recently,途扩®BroncTru® Disposable Bronchoscope Dilation Catheter(hereinafter referred to as '途扩®') successfully obtained approval from the Indonesian Ministry of Health, marking its official entry into the Indonesian market and achieving a new breakthrough in the Southeast Asian market. The Tuokuo® can achieve precise navigation to extraluminal lesion sites, especially peripheral solitary small pulmonary nodules that are not visible under X-ray, guided by a navigation system. It establishes a direct pathway to the lesion site for full-lung diagnosis and subsequent treatment. The dual-market introduction of Kunbo Medical's products in Hong Kong and Indonesia signifies its...
This follows the approval in Hong Kong of products such as Lung Point Plus, Archimedes, and Tuokuo® BroncTru®, with more innovative products from Kunbo Medical entering the precision pulmonary interventional diagnosis and treatment market in Hong Kong. These enrich the regional product portfolio and provide new precision interventional treatment options for local patients with lung diseases.
Indonesia
Recently,Tuokuo® BroncTru® Single-Use Bronchoscopic Dilation Catheter(hereinafter referred to as 'Tuokuo®') successfully obtained approval from the Indonesian Ministry of Health, marking a new breakthrough in the Southeast Asian market.
Hong Kong Recently, the self-developed product by堃博医疗,BroncAblate®智衡® Lung Radiofrequency Ablation System(including radiofrequency treatment equipment and a disposable lung radiofrequency ablation catheter, hereinafter referred to as '智衡®') has officially obtained the Hong Kong Department of Health Medical Device Listing (registration approval). This marks the formal commercial launch in Hong Kong of the world's first trans-natural airway radiofrequency ablation device for lung cancer interventional therapy. Concurrently,FleXNeedleCN Disposable Endoscopic Aspiration Biopsy Needlealso received the Hong Kong Department of Health Medical Device Listing (registration approval). Following the approval of products such as Lung Point Plus, Archimedes, and 途扩®BroncTru® in Hong Kong, more innovative products from堃博医疗 have entered Hong Kong’s precision lung interventional diagnostics and treatment market, enriching the regional product portfolio and providing new precise interventional diagnosis and treatment options for local lung disease patients. Indonesia Recently,途扩®BroncTru® Disposable Bronchoscope Dilation Catheter(hereinafter referred to as '途扩®') successfully obtained approval from the Indonesian Ministry of Health, marking its official entry into the Indonesian market and achieving a new breakthrough in the Southeast Asian market. The Tuokuo® can achieve precise navigation to extraluminal lesion sites, especially peripheral solitary small pulmonary nodules that are not visible under X-ray, guided by a navigation system. It establishes a direct pathway to the lesion site for full-lung diagnosis and subsequent treatment. The dual-market introduction of Kunbo Medical's products in Hong Kong and Indonesia signifies its...
Under the guidance of a navigation system, Tuokuo® can precisely reach extraluminal lesion sites, especially peripheral solitary pulmonary nodules invisible under X-ray, establishing a direct channel to the lesion for diagnosis and subsequent treatment across the entire lung.
The dual-market launch of堃博医疗’s products in Hong Kong and Indonesia marks an acceleration in its Asian market strategy, enriching the product pipeline layout in Asia and offering a new, safer, and more effective interventional diagnosis and treatment option for the large population of pulmonary patients in the region.
In the future, the company will continue to focus on the field of interventional respiratory treatments, promoting the global rollout of more innovative products to benefit even more patients.
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Thumbs Up
2
68K Views
Report
Comments
Write a Comment...
2
2